Role of bacillus Calmette–Guérin in the treatment of advanced melanoma

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines9(2), 209–222 (2010).
   PubMed Web of Science ®Google Scholar
• Paolillo A, Buzzi MG, Giugni E et al. The effect of bacille Calmette–Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J. Neurol.250(2), 247–248 (2003).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis.11(8), 633–640 (2011).
   PubMed Web of Science ®Google Scholar
• Yuk JM, Shin DM, Song KS et al. Bacillus Calmette–Guérin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy6(1), 46–60 (2010).
   PubMed Web of Science ®Google Scholar
• Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J. Urol.29(1), 59–71 (2010).
   Google Scholar
• Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med. Clin. North Am.60(3), 419–430 (1976).
   PubMed Web of Science ®Google Scholar
• de Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol. Res.19(1), 45–50 (1991).
   PubMedGoogle Scholar
• Kawai T, Akira S. TLR signaling. Semin. Immunol.19(1), 24–32 (2007).
   PubMed Web of Science ®Google Scholar
• Ludwig AT, Moore JM, Luo Y et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guérin-induced antitumor activity. Cancer Res.64(10), 3386–3390 (2004).
   PubMed Web of Science ®Google Scholar
• Kilbridge KL, Cole BF, Kirkwood JM et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data. J. Clin. Oncol.20(5), 1311–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Krone B, Kolmel KF, Grange JM et al. Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case–control study. Eur. J. Cancer39(16), 2372–2378 (2003).
   Google Scholar
• Kolmel KF, Gefeller O, Haferkamp B. Febrile infections and malignant melanoma: results of a case–control study. Melanoma Res.2(3), 207–211 (1992).
   PubMed Web of Science ®Google Scholar
• Kolmel KF, Grange JM, Krone B et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur. J. Cancer41(1), 118–125 (2005).
   PubMed Web of Science ®Google Scholar
• Pfahlberg A, Kolmel KF, Grange JM et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J. Invest. Dermatol.119(3), 570–575 (2002).
   Google Scholar
• Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette–Guérin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer100(8), 1692–1698 (2004).
   PubMed Web of Science ®Google Scholar
• Quirt IC, Shelley WE, Pater JL et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.9(5), 729–735 (1991).
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Rumke P, MacKie R, Morabito A, Bufalino R. The significance of conversion of skin reactivity to efficacy of bacillus Calmette–Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol. Immunother.28(4), 282–286 (1989).
   PubMed Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III Trial of bacillus Calmette–Guérin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma to regional or distant sites. J. Clin. Oncol. 2007 ASCO Ann. Meeting Proc.25(18 Suppl.), 8508 (2007).
   Google Scholar
• Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin.54(3), 131–149; quiz 182–184 (2004).
   PubMed Web of Science ®Google Scholar
• Roth JA, Silverstein MJ, Morton DL. Metastatic potential of metastases. Surgery79(6), 669–673 (1976).
   PubMed Web of Science ®Google Scholar
• Scadden DT. The stem-cell niche as an entity of action. Nature441(7097), 1075–1079 (2006).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr. Cancer Drug Targets7(1), 1 (2007).
   Google Scholar
• Mauti LA, Le Bitoux MA, Baumer K et al. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest.121(7), 2794–2807 (2011).
   PubMedGoogle Scholar
• Raychaudhuri B, Rayman P, Ireland J et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol.13(6), 591–599 (2011).
   PubMed Web of Science ®Google Scholar
• Goedegebuure P, Mitchem JB, Porembka MR et al. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr. Cancer Drug Targets11(6), 734–751 (2011).
   PubMed Web of Science ®Google Scholar
• de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol.13, 118–137 (2006).
   PubMedGoogle Scholar
• Lee HE, Park DJ, Kim WH, Kim HH, Lee HS. High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br. J. Cancer105(3), 413–419 (2011).
   PubMed Web of Science ®Google Scholar
• Liu F, Lang R, Zhao J et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat.130(2), 645–655 (2011).
   PubMed Web of Science ®Google Scholar
• Negin B, Panka D, Wang W et al. Effect of melanoma on immune function in the regional lymph node basin. Clin. Cancer Res.14(3), 654–659 (2008).
   Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14(1), 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol.18(12), 2444–2458 (2000).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol.19(9), 2370–2380 (2001).
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet351(9120), 1905–1910 (1998).
   PubMed Web of Science ®Google Scholar
• Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol.16(4), 1425–1429 (1998).
   PubMed Web of Science ®Google Scholar
• Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma. J. Clin. Oncol.22(1), 53–61 (2004).
   PubMed Web of Science ®Google Scholar
• Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon α 2b in high risk melanoma – the Scottish study. Br. J. Cancer84(9), 1146–1149 (2001).
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet358(9285), 866–869 (2001).
   PubMed Web of Science ®Google Scholar
• Garbe C, Radny P, Linse R et al. Adjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann. Oncol.19(6), 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet366(9492), 1189–1196 (2005).
   PubMed Web of Science ®Google Scholar
• Gogas H, Bafaloukos D, Ioannovich J et al. Tolerability of adjuvant high-dose interferon α-2b: 1 month versus 1 year – a Hellenic Cooperative Oncology Group study. Anticancer Res.24(3b), 1947–1952 (2004).
   Google Scholar
• Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet372(9633), 117–126 (2008).
   PubMed Web of Science ®Google Scholar
• Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung. Surgery107(3), 256–261 (1990).
   Google Scholar
• Harpole DH, Jr., Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg.103(4), 743–748; discussion 748–750 (1992).
   PubMed Web of Science ®Google Scholar
• Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am. J. Surg.162(5), 428–431 (1991).
   Google Scholar
• Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery115(3), 295–302 (1994).
   PubMedGoogle Scholar
• Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol.20(23), 4549–4554 (2002).
   PubMed Web of Science ®Google Scholar
• McLoughlin JM, Zager JS, Sondak VK. Cytoreductive surgery for melanoma. Surg. Oncol. Clin. N. Am.16(3), 683–693 (2007).
   Google Scholar